CompletedNot Applicable

System-IGF-1 Pathway and Alzheimer's Disease

France693 participantsStarted 2007-10

Plain-language summary

The aim is to assess the relationship between levels of IGF-I system components and cognitive status in patients with Alzheimer's disease (AD), in elderly subjects with normal cognitive function, and in patients with mild cognitive impairment (MCI).

Who can participate

Age range65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. elderly subjects with normal cognitive function,
✓. patients with dementia of AD type (DSM-IV and NINCDS-ADRDA criteria),
✓. patients with MCI (European Consortium on Alzheimer's Disease, EADC).

What they're measuring

Circulating IGF-I and IGFBP-3 levels in AD patients and control elderly subjects at the time of assessment(T0).

Timeframe: 24 hours

Trial details

NCT IDNCT00647478

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2010-10

View on ClinicalTrials.gov More Alzheimer's Disease trials